Histone Deacetylation
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Drugs in R&D
- Vol. 9 (6), 369-383
- https://doi.org/10.2165/0126839-200809060-00003
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2008
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancerInvestigational New Drugs, 2008
- Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.Blood, 2007
- Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia.Blood, 2007
- Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.Blood, 2007
- Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).Blood, 2007
- Regulation of COX-2–mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesisBlood, 2007
- Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) studyBlood, 2007
- Histone deacetylase regulation of immune gene expression in tumor cellsImmunologic Research, 2007
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005